EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers

Vasily Giannakeas, Adriana I Apostol, Claudia Diella, Nupur Dave, Jacek Gronwald, Robert Fruscio, Beth Y Karlan, Cezary Cybulski, Christian F Singer, Pål Møller, Raymond H Kim, Louise Bordeleau und 13 weitere

JAMA Surgery · 01.11.2026 · 161 (11) · 1192

DOI: 10.1001/jamasurg.2026.4356 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Surgery, erschienen am 01.11.2026. Verfasst von Vasily Giannakeas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Women's College Research and Innovation Institute, Women's College Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Salpingo-oophorectomy, Genes, BRCA1, Genes, BRCA2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Women with a BRCA1 or BRCA2 variant face a high lifetime risk of ovarian cancer and are often advised to undergo preventive surgery (bilateral salpingo-oophorectomy [BSO]) before cancer develops. The recommended age of BSO is 35 years for BRCA1 carriers and is 45 years for BRCA2 carriers, but some women choose to delay surgery until the age of menopause; there is no standard upper age at which surgery is no longer advised.

Objective

To estimate the residual lifetime risk of ovarian cancer among BRCA carriers by current age and projected age at BSO. Design, Setting, and Participants This was a prospective cohort study in an international cohort of BRCA carriers monitored for incident ovarian cancer. A life table analysis used age-specific ovarian cancer incidence rates and competing mortality rates to estimate lifetime risk of ovarian cancer among women with a BRCA1 or BRCA2 pathogenic variant with both ovaries intact and no prior ovarian cancer at baseline. Patients were recruited between 1995 and 2024 across 24 international centers, and the mean (SD) follow-up was 4.4 (3.9) years. Exposure Timing of BSO, defined as immediate BSO, delayed BSO, or no BSO. Main Outcome and Measures Residual lifetime risk of ovarian cancer.

Results

The cohort consisted of 4286 BRCA1 and 1427 BRCA2 carriers between the ages of 30 and 74 years at baseline (mean [SD] age, 42.0 [10.8] years). There were 249 incident ovarian cancers in the follow-up period. The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier and 24.1% (95% CI, 15.1-36.6) for a BRCA2 carrier. A 30-year-old BRCA1 carrier with BSO delayed to age 50 years had a projected residual ovarian cancer risk of 23.9% (95% CI, 20.7-27.4). At age 75 years, the residual risk of ovarian cancer was estimated to be 8.4% (95% CI, 1.7-22.7) for a BRCA1 carrier and 3.7% (95% CI, 0.1-22.7) for a BRCA2 carrier. Conclusions and Relevance The residual risk of ovarian cancer for older women in good health is sufficiently high to consider preventive surgery. BRCA1 carriers who defer BSO until age 50 years may face a substantial risk of developing ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsSalpingo-oophorectomyGenes, BRCA1Genes, BRCA2HumansFemaleMiddle AgedAdultProspective StudiesAge FactorsHeterozygoteIncidenceAged

Autor:innen und Institutionen

  • Women's College Research and Innovation Institute, Women's College Hospital, Toronto, Ontario, Canada.
  • Now with Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
  • Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  • Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy.

Zitieren

APA

Giannakeas, V., Apostol, A. I., Diella, C., Dave, N., Gronwald, J., Fruscio, R., Karlan, B. Y., Cybulski, C., Singer, C. F., Møller, P., Kim, R. H., Bordeleau, L., Ramón Y Cajal, T., Pal, T., Eisen, A., Couch, F. J., Zakalik, D., Metcalfe, K., Tung, N., …, & Hereditary Ovarian Cancer Clinical Study Group (2026). Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers. JAMA Surgery, 161(11), 1192. https://doi.org/10.1001/jamasurg.2026.4356

Vancouver

Giannakeas V, Apostol AI, Diella C, Dave N, Gronwald J, Fruscio R, et al. Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers. JAMA Surgery. 2026;161(11):1192. doi:10.1001/jamasurg.2026.4356

BibTeX
@article{Giannakeas2026,
  author = {Giannakeas, Vasily and Apostol, Adriana I and Diella, Claudia and Dave, Nupur and Gronwald, Jacek and Fruscio, Robert and Karlan, Beth Y and Cybulski, Cezary and Singer, Christian F and Møller, Pål and Kim, Raymond H and Bordeleau, Louise and Ramón Y Cajal, Teresa and Pal, Tuya and Eisen, Andrea and Couch, Fergus J and Zakalik, Dana and Metcalfe, Kelly and Tung, Nadine and Aeilts, Amber and Sun, Ping and Lubinski, Jan and Kotsopoulos, Joanne and Narod, Steven A and Hereditary Ovarian Cancer Clinical Study Group, Hereditary Ovarian Cancer Clinical Study Group},
  title = {Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers},
  journal = {JAMA Surgery},
  year = {2026},
  volume = {161},
  number = {11},
  pages = {1192},
  doi = {10.1001/jamasurg.2026.4356}
}
Kostenlos starten →